NCT00111891View on ClinicalTrials.gov

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

PHASE2CompletedINTERVENTIONAL
Enrollment

575

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Dyslipidemia
Interventions
DRUG

niacin (+) laropiprant

DRUG

Comparator: placebo (unspecified)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00111891 - An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032) | Biotech Hunter | Biotech Hunter